DENVER / Mar 08, 2023 / Business Wire / Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced that Heath Sampson, Modivcare’s President and Chief Executive Officer, is scheduled to participate in a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023, at 4:00 p.m. Eastern Time. Management will also host virtual investor meetings throughout the day.
A link to the live webcast of the Company’s presentation can be found on Modivcare’s Investor Relations website at Modivcare Inc. - Investor Overview. A replay of the presentation will be available for 90 days following the date of the presentation.
About Modivcare
Modivcare Inc. (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their members. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com.
Last Trade: | US$0.99 |
Daily Change: | -0.13 -11.61 |
Daily Volume: | 657,279 |
Market Cap: | US$14.080M |
March 06, 2025 October 23, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load